ArriVent BioPharma, Inc. (AVBP): Total Assets
$333.17M
As of 2025-12-31
$394.72M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $333.17M | +21.2% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $274.94M | +68.6% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $163.10M | n/a | 2025-03-03, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | $333.17M | +21.2% |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | $332.64M | +71.8% |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | $330.45M | -37.4% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $327.65M | -6.7% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $340.05M | -30.7% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $325.95M | +75.5% |
Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗